This morning I laid out my general approach to how I’d deal with PEDs and the Hall of Fame. The shorthand: I’m a discounter. I try my best to take the accomplishment of established PED users down a bit. In this way I’m making an extremely rough and dirty era adjustment. I know it’s not a bulletproof approach. Far from it. And whenever I offer it up I usually ask for people if they have better ideas to enlighten me, because there isn’t a great way to deal with it.
Brien over at IIATMS took me up on that this afternoon, offering a critique of my approach that, I must acknowledge, makes me feel somewhat uncomfortable with my approach:
To sum it all up, the “this player wouldn’t be Hall-worthy without ‘roids” premise seems superficially fair and nuanced, but getting below the surface it seems far too similar to the old “he just doesn’t feel like a Hall-of-Famer” chestnut to me, and I absolutely despise that standard. And that’s why, though I certainly understand the desire to try to find a nuanced way to view this question, ultimately I don’t think there’s any way to apply such a standard in anything approaching an objective or scientific faction.
I can’t really rebut that with any sort of force. But I’m still not comfortable with where Brien comes out, which is to totally ignore the potential impact of PED use and focus only on production.
There’s no perfect answer here. It’s a struggle for even a guy like me who is often called a steroids apologist.
Update (7:01 PM EDT): David O’Brien of the Atlanta Journal-Constitution reports the deal has been completed.
ESPN’s Keith Law reported on Saturday evening that a bad contract swap involving the Braves’ Hector Olivera and the Padres’ Matt Kemp was “getting close.” Olivera has been pulled off the field, per Bob Nightengale of USA TODAY. Joel Sherman of the New York Post reports that only a last-second medical would kill the deal at this point, and that the Padres will be sending money to the Braves.
Kemp, 31, will have $64.5 million remaining on his contract through 2019 after this season, but the Dodgers will pay $3.5 million annually over those remaining three years, so the $64.5 million is really $54 million. The veteran has compiled a .262/.285/.489 triple-slash line with 23 home runs and 69 RBI in 431 plate appearances for the Padres this season.
Olivera, 31, will have $28.5 million remaining on his contract through 2020 after this season. The outfielder was handed an 82-game suspension, beginning on May 26, for his involvement in a domestic dispute on April 13. The suspension is up on August 2. He has a .501 OPS in 21 major league at-bats this season and a .278 OPS in 37 PA at Triple-A.
Dennis Lin of the San Diego Union-Tribune reports that the Padres will consider designating Olivera for assignment. The trade is all about the salary dump for the Padres, as they’d rather give outfield playing time to prospects Hunter Renfroe and Manuel Margot.
The Athletics and Royals swapped outfielders on Saturday. The Athletics sent Billy Burns to Kansas City and the Royals sent Brett Eibner to Oakland.
Burns, 26, doesn’t provide much in the way of offense, but he runs the bases well and plays solid defense. He was hitting .234/.270/.303 with 11 doubles, four triples, and 14 stolen bases in 274 plate appearances.
Eibner, 27, was batting .231/.286/.423 with three home runs and 10 RBI in 85 plate appearances. He has spent most of the season with Triple-A Omaha, where he’s put up a .902 OPS in 219 PA. Eibner played the outfield corners in the majors, but racked up a ton of time playing center in the minors, so his versatility will be valuable to the A’s.
Burns will become eligible for arbitration for the first time after the 2017 season while Eibner has hardly accrued any service time, which might explain part of the motivation behind the trade for the small-market Athletics.